Alaunos Therapeutics, Inc.
TCRTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Alaunos Therapeutics, Inc. (TCRT) is listed under Biotechnology. At a $6.7M market cap, Alaunos Therapeutics, Inc. ranks as a micro-cap company within healthcare. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Market Cap
$6.7M
Beta
-0.87
P/E (TTM)
—
P/E (Fwd)
-3.80
EPS (TTM)
$-1.76
EPS (Fwd)
$-0.60
ROE
-185.9%
ROA
-81.1%
Cash
$124,000
Total Debt
$0
Free CF
-$1.6M
52W Change
-19.1%
Annual Financials
Cash vs Debt
Where TCRT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TCRT finished 44.91% above its 150-day moving average ($2.16) and 32.63% above its 200-day moving average ($2.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TCRT overbought or oversold?
At the October 20, 2026 close, TCRT's RSI(14) was 73.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Alaunos Therapeutics, Inc. reports $124K in cash and $0 in total debt. The company is burning cash, with free cash flow at -$1.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -185.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $2.9M (2022) to $5K (2025), a 100% decline worth watching.
With a beta below 0.7, Alaunos Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alaunos Therapeutics, Inc. and its sector.